MSH2 and Lynch syndrome: Additionally, there would appear to be reason to focus this surveillance on patients with Lynch syndrome who carry pathogenic variants in MSH2, MLH1 and (probably) EpCAM, but not do this on patients with MSH6 pathogenic variants (probably) and PMS2 (certainly).